AC Immune SA (ACIU) is a publicly traded Healthcare sector company. As of May 21, 2026, ACIU trades at $2.95 with a market cap of $281.91M and a P/E ratio of 0.00. ACIU moved +2.13% today. Year to date, ACIU is -17.90%; over the trailing twelve months it is +65.14%. Its 52-week range spans $1.43 to $4.00. Analyst consensus is strong buy with an average price target of $10.00. Rallies surfaces ACIU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
AC Immune CEO Andrea Pfeifer to retire after 23 years; Dr Martin Zügel interim CEO: Dr Andrea Pfeifer retires as AC Immune CEO after 23 years, with Board Chair Dr Martin Zügel named interim CEO at the upcoming AGM. Pfeifer remains Advisor and Honorary Board Chair as the company advances three clinical candidates and deepens partnerships with Lilly, Takeda and J&J.
| Metric | Value |
|---|---|
| Price | $2.95 |
| Market Cap | $281.91M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.00 |
| 52-Week Low | $1.43 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover ACIU: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.00.